{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:32Z","timestamp":1784998952683,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Germline\n                      <jats:italic>BRCA<\/jats:italic>\n                      (gBRCA) mutations and homologous recombination deficiency (HRD) are critical factors affecting treatment response; however, their association with hematologic toxicity remains controversial. This study assessed the interplay between these molecular features and hematologic adverse events during platinum\u2013taxane chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 62 patients with stage III\u2013IV ovarian cancer between 2022 and 2024. After excluding 8 patients, 54 patients were stratified according to gBRCA and HRD status, and hematologic adverse events were evaluated for up to six treatment cycles. Moreover, meta-analysis was performed to integrate previously published data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>First, after excluding patients with uncertain gBRCA status, eight gBRCA mutation carriers were compared with 33 confirmed non-carriers. gBRCA mutation carriers tended to exhibit lower neutrophil counts during treatment; however, no statistically significant differences in hematologic toxicities were observed across treatment cycles. In the pooled meta-analysis, gBRCA mutation carriers demonstrated significantly increased odds of neutropenia (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.16\u20132.44) and G-CSF use (OR 3.09, 95% CI 1.19\u20138.03), whereas no significant associations were observed for anemia, thrombocytopenia, dose delay, or dose reduction. Second, 23 HRD-positive patients and 15 HRD-negative patients were analyzed. HRD-positive patients did not demonstrate increased hematologic toxicity compared with HRD-negative patients. Although baseline hemoglobin levels were lower in HRD-positive patients, these differences preceded chemotherapy initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides real-world evidence of a modestly increased risk of neutropenia and G-CSF use in gBRCA carriers during platinum\u2013taxane chemotherapy; however, these differences did not appear to compromise treatment delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03065-4","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:55:14Z","timestamp":1779900914000},"page":"1576-1586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum\u2013taxane chemotherapy in ovarian cancer"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-4872","authenticated-orcid":false,"given":"Kosuke","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Masahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiri","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komei","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Kubokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Mogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"3065_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"3065_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso G, Weroha SJ, Cliby W (2025) Ovarian cancer: a review. JAMA 334(14):1278\u20131291. https:\/\/doi.org\/10.1001\/jama.2025.9495","journal-title":"JAMA"},{"issue":"4","key":"3065_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195(4):451\u2013456. https:\/\/doi.org\/10.1002\/path.1000","journal-title":"J Pathol"},{"issue":"10","key":"3065_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10):719\u2013725. https:\/\/doi.org\/10.1038\/nrc3144","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"3065_CR5","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.7112","journal-title":"JAMA"},{"key":"3065_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","volume":"14","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB (2014) Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 14:150. https:\/\/doi.org\/10.1186\/s12905-014-0150-5","journal-title":"BMC Womens Health"},{"issue":"26","key":"3065_CR7","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, St\u00e4hle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1103799","journal-title":"N Engl J Med"},{"issue":"8","key":"3065_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, Nagao S, Vergote I, Colombo N, M\u00e4enp\u00e4\u00e4 J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P (2023) Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol 34(8):681\u2013692. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005","journal-title":"Ann Oncol"},{"issue":"25","key":"3065_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O\u2019Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-P\u00e9rez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"issue":"9","key":"3065_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balma\u00f1a J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS (2019) A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 30(9):1437\u20131447. https:\/\/doi.org\/10.1093\/annonc\/mdz192","journal-title":"Ann Oncol"},{"issue":"1","key":"3065_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/igc.0000000000001144","volume":"28","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T (2018) BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer. Int J Gynecol Cancer 28(1):69\u201376. https:\/\/doi.org\/10.1097\/igc.0000000000001144","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"3065_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ygyno.2019.04.009","volume":"154","author":"F Tomao","year":"2019","unstructured":"Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P (2019) Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecol Oncol 154(1):138\u2013143. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.009","journal-title":"Gynecol Oncol"},{"issue":"12","key":"3065_CR13","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1634\/theoncologist.2019-0272","volume":"24","author":"O Weitzner","year":"2019","unstructured":"Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L (2019) Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy. Oncologist 24(12):e1471\u2013e1475. https:\/\/doi.org\/10.1634\/theoncologist.2019-0272","journal-title":"Oncologist"},{"issue":"1","key":"3065_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00280-024-04670-8","volume":"94","author":"IH Lee","year":"2024","unstructured":"Lee IH, Lee SJ, Kim J, Lee YH, Chong GO, Kim JM, Lee J, Lee NY, Park SY, Hong DG, Chae YS (2024) Exploring the effect of BRCA1\/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. Cancer Chemother Pharmacol 94(1):103\u2013108. https:\/\/doi.org\/10.1007\/s00280-024-04670-8","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3065_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10689-023-00331-6","volume":"22","author":"K Hu-Heimgartner","year":"2023","unstructured":"Hu-Heimgartner K, Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, Vazquez C, Friedlaender A, Vuilleumier A, Bodmer A, Viassolo V, Sandoval JL, Chappuis PO, Labidi-Galy SI (2023) Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1\/BRCA2 germline pathogenic variants. A single center experience and review of the literature. Fam Cancer 22(3):283\u2013289. https:\/\/doi.org\/10.1007\/s10689-023-00331-6","journal-title":"Fam Cancer"},{"issue":"3","key":"3065_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10549-018-05127-2","volume":"174","author":"A Friedlaender","year":"2019","unstructured":"Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD, Peron J, Bodmer A, Giraud S, Buisson A, Bonadona V, Gauchat-Bouchardy I, Tredan O, Chappuis PO, Labidi-Galy SI (2019) BRCA1\/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Res Treat 174(3):775\u2013783. https:\/\/doi.org\/10.1007\/s10549-018-05127-2","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"3065_CR17","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1158\/1078-0432.Ccr-06-1246","volume":"12","author":"S Shanley","year":"2006","unstructured":"Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G, Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R (2006) Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 12(23):7033\u20137038. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-1246","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3065_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10549-016-3777-0","volume":"156","author":"JC Drooger","year":"2016","unstructured":"Drooger JC, Heemskerk-Gerritsen BAM, Smallenbroek N, Epskamp C, Seynaeve CM, Jager A (2016) Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer. Breast Cancer Res Treat 156(3):557\u2013566. https:\/\/doi.org\/10.1007\/s10549-016-3777-0","journal-title":"Breast Cancer Res Treat"},{"key":"3065_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2020.12.007","volume":"145","author":"J Furlanetto","year":"2021","unstructured":"Furlanetto J, M\u00f6bus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, L\u00fcbbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA (2021) Germline BRCA1\/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 145:44\u201352. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.007","journal-title":"Eur J Cancer"},{"issue":"4","key":"3065_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr","year":"1971","unstructured":"Knudson AG Jr. (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68(4):820\u2013823. https:\/\/doi.org\/10.1073\/pnas.68.4.820","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3065_CR21","doi-asserted-by":"publisher","first-page":"e100068","DOI":"10.1371\/journal.pone.0100068","volume":"9","author":"HE Feilotter","year":"2014","unstructured":"Feilotter HE, Michel C, Uy P, Bathurst L, Davey S (2014) BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development. PLoS ONE 9(6):e100068. https:\/\/doi.org\/10.1371\/journal.pone.0100068","journal-title":"PLoS ONE"},{"issue":"1","key":"3065_CR22","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1038\/ncomms6496","volume":"5","author":"S Pathania","year":"2014","unstructured":"Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, Livingston DM (2014) BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 5(1):5496. https:\/\/doi.org\/10.1038\/ncomms6496","journal-title":"Nat Commun"},{"issue":"43","key":"3065_CR23","doi-asserted-by":"publisher","first-page":"17773","DOI":"10.1073\/pnas.1110969108","volume":"108","author":"H Konishi","year":"2011","unstructured":"Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH (2011) Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A 108(43):17773\u201317778. https:\/\/doi.org\/10.1073\/pnas.1110969108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3065_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/15384101.2016.1141841","volume":"15","author":"M Sedic","year":"2016","unstructured":"Sedic M, Kuperwasser C (2016) BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer. Cell Cycle 15(5):621\u2013627. https:\/\/doi.org\/10.1080\/15384101.2016.1141841","journal-title":"Cell Cycle"},{"key":"3065_CR25","doi-asserted-by":"publisher","first-page":"115169","DOI":"10.1016\/j.ejca.2024.115169","volume":"215","author":"S Quesada","year":"2025","unstructured":"Quesada S, Penault-Llorca F, Matias-Guiu X, Banerjee S, Barberis M, Coleman RL, Colombo N, DeFazio A, McNeish IA, Nogueira-Rodrigues A, Oaknin A, Pignata S, Pujade-Lauraine \u00c9, Rouleau \u00c9, Ry\u0161ka A, Van Der Merwe N, Van Gorp T, Vergote I, Weichert W, Wu X, Ray-Coquard I, Pujol P (2025) Homologous recombination deficiency in ovarian cancer: global expert consensus on testing and a comparison of companion diagnostics. Eur J Cancer 215:115169. https:\/\/doi.org\/10.1016\/j.ejca.2024.115169","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03065-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:39Z","timestamp":1784997339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03065-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3065"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03065-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest.","order":1,"name":"Ethics","label":"Coflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}